FirsthandHealth
medRxiv PreprintsInternational15 November 2026

FlahyRecovery is an AI & gene expression based immune profiling biomarker for decision support in precision oncology

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background Accurate characterization of the tumor microenvironment (TME) is crucial for inferring tumor biology, subsequent tumor behavior, and predicting therapeutic response. Current characterization methods are inadequate in capturing the complexity of immune signaling networks, hindering robust clinical decision making. To address this, we have developed FlahyRecovery - an artificial intelligence (AI) and gene expression based immune profiling biomarker, implemented via a supervised classification machine learning model, that integrates response prediction and prognostic insights to person
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.